IP Library Granted Patent US 7,524,821
Granted Patent B2
US 7,524,821 · App. 10/518,108 · Granted Apr 28, 2009

Scaffolded maleimide clusters for multivalent peptide assembly

Assignee: University of Maryland Biotechnology Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,821
App. No.
10/518,108
Granted
Apr 28, 2009
Kind
B2
Abstract

Disclosed are scaffolded maleimide clusters, methods of making said clusters and use of said clusters as templates for multivalent peptide assembly. Multiple maleimide functionalities were introduced onto a scaffold molecule by the reaction of a core-centered polyamines with methoxycarbonylmaleimide or with activated esters of maleimide-containing compounds. The scaffolded maleimides allow rapid, highly chemoselective, and high-yield ligation with thiolcontaining peptides under virtually neutral conditions at room temperature. The disclosed mild and highly efficient ligation method is extremely valuable for synthesizing large and complex multivalent peptides that may not be easily obtained by conventional ligation methods. These novel scaffolded maleimide clusters allow a highly chemoselective ligation with a thiolcontaining peptide under virtually neutral conditions, providing a new and efficient approach for multivalent peptide assembly. The disclosed mild and highly efficient ligation method is extremely valuable for synthesizing large and complex multivalent peptides that may not be easily obtained by conventional ligation methods. A series of multivalent peptides containing the sequence of the 36-mer HIV-1 inhibitor DP178 (T20), the T-helper epitope from tetanus toxoid (830-844), and the minimum epitope sequence of the potent HIV-neutralizing antibody 2F5 were synthesized. Carbohydrates and cholic acid were chosen as the scaffold because of their rigidity and mufti-functionality. Thus, the topology of the multivalent peptides can be controlled by the defined spatial orientation of the maleimide functionalities on the rigid scaffold core. The resulting multivalent gp41 peptides incorporating strands of DP178 on the monosaccharide and the cholic acid templates were found to be able to form three or four a-helix bundles. Moreover, the multivalent peptides containing strands of the long gp41 peptide DP178 were highly immunogenic and were able to raise high titers of peptide-specific antibodies in the absence of any additional adjuvant. Therefore, these and related multivalent peptides constructed on the maleimide clusters may be used as novel immunogens, potential inhibitors, protein mimics, artificial proteins, and powerful antigens for a broad range of biomedical applications.

Claims (10)

1. A maleimide cluster comprising a core carbohydrate molecule wherein the core is selected from the group consisting of monosaccharides, oligosaccharides, and cyclic oligosaccharides and wherein at least two or more maleimide containing groups are attached to the core, wherein the maleimide containing groups are linked to the carbohydrate core by an alkyl cysteamine linker and optionally comprising a protein is covalently attached to the maleimide.

2. The maleimide cluster according to claim 1 , wherein the core carbohydrate molecule is a monosaccharide.

3. The maleimide cluster according to claim 2 wherein four or more maleimide containing groups are attached to the core by the linker.

4. The maleimide cluster according to claim 1 , wherein the core comprises cyclodextrin and wherein one or more maleimide containing groups are each attached to the cyclodextrin.

5. The maleimide cluster of claim 2 further comprising a protein covalently attached to each of the maleimide containing groups, wherein proteins attached to the maleimide containing groups have the same or different amino acid sequences.

6. A method of delivering a peptide drug comprising administering a multivalent peptide containing a therapeutically effective amount of the peptide drug to a patient in need thereof, wherein the multivalent peptide comprises peptides covalently attached to the maleimide cluster of claim 2 .

7. The method of claim 6 , wherein the covalently attached peptides comprise the same or different amino acid sequences.

8. A method of making a multivalent protein comprising contacting proteins containing a thiol group with the maleimide cluster according to claim 2 and forming a covalent bond thereto.

9. The method of claim 8 , wherein the covalently bonded proteins the same or different amino acid sequences.

10. The maleimide cluster according to claim 2 comprising a protein covalently attached to each maleimide containing groups, wherein the protein is an HIV antigen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2005
From: WANG, LAI-XI; NI, JIAHONG; LI, HENGGUANG; SINGH, SUDDHAM
To: UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE
Reel/Frame 015820/0264 →
Continuity (2)
Provisional Application 6039077600 · Jun 20, 2002
Related Publication 20050159341A1 · Jul 21, 2005